C200 schreef op 28 mei 2020 20:05:
[...]
Ik vind dit stukje wel leuk, vooral die 25% in de onderste alinea.
The company's drug portfolio here is performing well. Filgotinib has a massive timeline during which it can be earning revenue, with patient expiration not expected until the late-2030s. Peak sales of the drug are expected to come in at $4-6 billion annually, versus the company's current annualized revenue of roughly $20 billion.
That means Filgotinib represents 25% of the company's 2020 to late-2030s potential business.
seekingalpha.com/article/4350568-gile...